Your browser doesn't support javascript.
loading
: 20 | 50 | 100
1 - 4 de 4
1.
N Z Med J ; 134(1530): 38-47, 2021 02 19.
Article En | MEDLINE | ID: mdl-33651776

AIMS: We aimed to assess the use of and attitudes towards cannabis use (medicinal and recreational) by people with IBD in New Zealand. METHODS: People with IBD were invited to complete an anonymous online questionnaire. Participants were recruited via postal mail using a hospital database of patients with IBD (developed by the Gas-troenterology Department at Dunedin Public Hospital) and via online recruitment (advertised on the Crohn's and Colitis New Zealand website, Facebook page and e-mail list). Inclusion criteria were ages 18+ and self-reported confirmed IBD diagnosis. RESULTS: In total, 378 participants completed the questionnaire, with 334 eligible responses. Partici-pants were predominantly New Zealand European (84%) and female (71%). Sixty-one percent of re-spondents had CD and 34% UC. Overall, 51% of respondents reported having ever used cannabis. Of those, 63% reported use as recreational and 31% for reduction of IBD symptoms. Users were more likely to be younger (on average by 6.4 years), with on-going symptoms, unemployed or self-employed and current or ex-smokers. There were no differences by disease status or severity. Symp-toms most reported as improved by cannabis use were abdominal pain/cramping, nausea/vomiting and loss of appetite. Fifty-four percent of participants reported that if cannabis were legal, they would request it for medicinal use to help manage their symptoms. CONCLUSIONS: Overall, our research aligns with previous observational research that reports im-provements in symptoms of IBD with cannabis use. Studies of a higher evidence level (eg, RCTs) would be needed to guide prescribing. In the meantime, this research provides useful background to clini-cians about patients' views and experiences.


Attitude , Cannabis/adverse effects , Inflammatory Bowel Diseases/drug therapy , Phytotherapy/statistics & numerical data , Adolescent , Adult , Aged , Colitis, Ulcerative/drug therapy , Colitis, Ulcerative/psychology , Crohn Disease/drug therapy , Crohn Disease/psychology , Drug Utilization/statistics & numerical data , Female , Humans , Inflammatory Bowel Diseases/psychology , Male , Middle Aged , New Zealand , Phytotherapy/methods , Plant Extracts/therapeutic use , Self Medication/statistics & numerical data , Self Report , Young Adult
2.
Int J Geriatr Psychiatry ; 35(5): 516-524, 2020 05.
Article En | MEDLINE | ID: mdl-31957058

BACKGROUND: As the economic impact of dementia on health and social care increases, governments require disease-specific epidemiological data that will help inform spending and policy decisions. The aim of this study is to examine predictors of mortality in dementia in consecutive referrals to a New Zealand (NZ) memory service that includes Maori, Pacific Islander, and NZ European patients. METHODS: Date of birth, sex, ethnicity, living situation, cognitive function, dementia subtype, dementia severity, physical comorbidity, and medication data were collected from electronic health records. The resulting data set was linked to administrative data on mortality and last hospital contact dates to allow time-dependent survival analyses. RESULTS: The risk of death in people with dementia was increased by age (adjusted HR per year 1.08, 95%CI:1.05-1.12) and lower cognitive score at baseline (adjusted HR for severe impairment:2.54, 95% CI:1.25-5.16), and was reduced by cholinesterase inhibitors (adjusted HR:0.54, 95% CI:0.34-0.88). Compared to NZ Europeans (HR:1.19, 95% CI:0.63-2.25), antipsychotics increased the risk of death three-fold in Maori (adjusted HR:3.62, 95% CI:0.79-16.7) and Pacific Islanders (adjusted HR:2.54, 95%CI:1.10-5.85). CONCLUSIONS: Further research is required to elucidate the mechanisms underlying the survival rates in Maori and Pacific Islanders living with dementia in NZ,and their increased risk of death if antipsychotics are used.


Dementia/mortality , Mortality/ethnology , Native Hawaiian or Other Pacific Islander/statistics & numerical data , White People/statistics & numerical data , Antipsychotic Agents/therapeutic use , Cholinesterase Inhibitors/therapeutic use , Comorbidity , Dementia/diagnosis , Dementia/drug therapy , Female , Humans , Male , Middle Aged , Mortality/trends , New Zealand/epidemiology , Pacific Islands/ethnology
3.
Int J Geriatr Psychiatry ; 34(12): 1758-1764, 2019 12.
Article En | MEDLINE | ID: mdl-31389087

OBJECTIVE: The number of Asian New Zealanders with dementia is growing. The objective of this study was to explore with a group of Asian health care professionals about public attitudes towards dementia in Asian communities in New Zealand, the stigma of dementia, and how best to develop culturally appropriate services for Asian people and families living with dementia. METHODS: A focus group was conducted with a group of bilingual Asian health care professionals. A topic guide was developed based on the discussion at a prior meeting with the Cross Cultural Interest Group. The data were independently analysed by three researchers using the thematic qualitative methodology. RESULTS: Eleven overseas-born Asian health care professionals (Chinese: n = 9, 82%) participated in the focus group. Four main themes emerged from the data: (a) cultural interpretations of dementia; (b) stigma; (c) filial piety; and (d) inequity in the availability of resources. CONCLUSION: Our findings suggest that much work is needed to destigmatise dementia in New Zealand Asian communities, through psychoeducation, public awareness, and the availability of readily accessible services that can meet their cultural and language needs.


Asian People , Attitude of Health Personnel , Dementia/psychology , Adult , Female , Focus Groups , Health Knowledge, Attitudes, Practice , Humans , Male , Middle Aged , New Zealand , Prejudice
...